Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIL-15 and Alemtuzumab for Refractory/Relapsed ATL
NCT02689453Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2017
- Primary completion
- Jun 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of recombinant human interleukin-15 in adult T-cell leukemia/lymphoma (ATLL), peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL) and 1 more (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 6 weeks, Dose-limiting Toxicities at 6 weeks and 1 more. Started Jan 2017; status: completed.
02
Drugs
recombinant human interleukin-15
03
Conditions
adult T-cell leukemia/lymphoma (ATLL)peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on NCT02689453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689453.